Trodelvy (sacituzumab govitecan) – A new effective treatment option for breast cancer
Data presented at SABCS22 shows that Trodelvy, sacituzumab govitecan, is an effective new treatment option for patients with pre-treated, endocrine-resistant HR+/HER2- metastatic breast cancer.